Iovance Biotherapeutics, Inc. cash flow to debt ratio of -624.24% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Iovance Biotherapeutics, Inc.'s free cash flow has increased -7.64% from $-364.05M last year to $-336.24M, signaling increasing performance

Iovance Biotherapeutics, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Iovance Biotherapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.08 last year to 0.06 today, signaling strengthened financials

Iovance Biotherapeutics, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Iovance Biotherapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Iovance Biotherapeutics, Inc.'s profit margin has increased (-60.73%) in the last year from -226.84% to -89.09%, signaling increasing performance

Iovance Biotherapeutics, Inc.'s short-term assets of $442.69M exceed its short-term liabilities of $138.36M

Iovance Biotherapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Iovance Biotherapeutics, Inc.'s return on equity of -40.51%, is lower than 15.00%, indicating bad performance

Iovance Biotherapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Iovance Biotherapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Iovance Biotherapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Iovance Biotherapeutics, Inc. has negative free cash flow, indicating cash burn

Iovance Biotherapeutics, Inc.'s yearly earnings has decreased 5.05% since last year from $-372.18M to $-390.98M, signaling decreasing performance

Iovance Biotherapeutics, Inc.'s yearly revenue has increased 60.60% since last year from $164.07M to $263.50M, signaling increasing performance

ROIC -36.60% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Iovance Biotherapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Iovance Biotherapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Iovance Biotherapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Iovance Biotherapeutics, Inc. has insufficient data to evaluate this check.

Iovance Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Iovance Biotherapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Iovance Biotherapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Iovance Biotherapeutics, Inc. has insufficient data to evaluate this check.

Iovance Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Iovance Biotherapeutics, Inc. has a price-to-book ratio of 3.91x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Iovance Biotherapeutics, Inc. has a price-to-sales ratio of 8.87x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue